Biomimetic Janus aAPCs With Bull's-Eye Ligands for T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic particles used as artificial antigen-presenting cells (aAPCs) do not effectively mimic the three-dimensional structure of native antigen-presenting cells (APCs), leading to inconsistent T cell activation and requiring time-consuming and expensive isolation of native APCs.
Innovation Solution
Development of biomimetic Janus particles with 'bull's eye' ligand patterns on nano- or micro-sized particles that mimic either the native or reverse organization of the T cell immunological synapse, using methods like microcontact printing and block copolymer self-assembly to create distinct ligand populations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native APCs are isolated for T cell-based immunotherapy, then T cell activation can be achieved, but the process is time-consuming and expensive
Solution Approach 1:
The patent creates artificial APCs that copy the essential functional features of native APCs - specifically displaying antigen peptides and co-stimulatory ligands on their surface in a configuration that mimics the immunological synapse. This allows T cell activation without requiring isolation of native APCs, thus resolving the contradiction between effectiveness and time consumption
Solution Approach 2:
The patent modifies the physical and chemical parameters of synthetic particles to optimize T cell activation. This includes controlling particle size (1-10 μm), surface ligand density, and spatial arrangement of antigens and co-stimulatory molecules. By optimizing these parameters, the artificial APCs achieve effective T cell activation while eliminating the time-consuming isolation process
2Ease of manufacture
If synthetic particles are randomly coated with proteins, then production is simplified, but they do not truly mimic the native immunological synapse
Solution Approach 1:
The patent applies local quality by creating distinct spatial zones on the particle surface with different ligand compositions. The immunological synapse-mimicking configuration places antigen-presenting MHC molecules and co-stimulatory ligands (CD80, CD86, ICAM-1) in specific spatial arrangements that replicate the native APC-T cell interface, rather than random distribution
Solution Approach 2:
The patent transitions from two-dimensional random surface coating to three-dimensional controlled spatial arrangement. The ligands are organized in specific spatial configurations that mimic the nanoscale organization of the immunological synapse, adding a dimension of structural precision to the manufacturing process
Data Source
AI summary
Described herein are biomimetic Janus particles useful as artificial antigen presenting cells capable of activating T cells in vitro. “Bull's eye” ligand patterns mimicking either the native or reverse organization of the T cell immunological synapse are provided on the surface of nano- or micro-sized particles. Methods for activating T cells in vitro using biomimetic Janus particles described herein are also provided. T cells activated by the biomimetic Janus particles can be used in adoptive immunotherapies for treating cancer, tolerance induction in autoimmune disease, autologous immune enhancement therapy, and viral infection immunotherapy. Also described herein are methods for producing a biomimetic Janus particle.